OverviewSuggest Edit

Oncology Venture is a drug development company dedicated to unlocking the potential of oncology products and rescue failed drugs. Its method promotes the efficacy of the drugs, increase the response rate in cancer patients, reduce timelines, and improve success rates in oncology drug development.
TypePublic
Founded2004
HQHørsholm, DK
Websiteoncologyventure.com

Latest Updates

Employees (est.) (Dec 2018)12
Share Price (Sept 2020)KR1.6 (-3%)
Cybersecurity ratingAMore

Key People/Management at Oncology Venture

Duncan Moore

Duncan Moore

Chairman of the Board, Independent Board Member
Henrik Moltke

Henrik Moltke

Chief Financial Officer
Frank Knudsen

Frank Knudsen

Deputy Chairman of the Board, Independent Board Member
Steen Knudsen

Steen Knudsen

Chief Scientific Officer, Director
Steve Carchedi

Steve Carchedi

CEO, Director
Marie Foegh

Marie Foegh

Chief Medical Officer
Show more

Oncology Venture Office Locations

Oncology Venture has offices in Hørsholm and Scottsdale
Hørsholm, DK (HQ)
Venlighedsvej 1
Scottsdale, US
9977 N 90th St #175
Show all (2)

Oncology Venture Financials and Metrics

Oncology Venture Revenue

Market capitalization (15-Sept-2020)

300.5m

Closing stock price (15-Sept-2020)

1.6
Oncology Venture's current market capitalization is kr300.5 m.
Show all financial metrics

Oncology Venture Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Oncology Venture Online and Social Media Presence

Embed Graph

Oncology Venture News and Updates

Press Release Oncology Venture Publishes Interim Report for the Period January – June 2020

Hørsholm, Denmark (28 August 2020) – Oncology Venture A/S (OV:ST) (“Oncology Venture”) today announces the Interim Report for the period January – June 2020. The report is available as an attached document and on the company’s website.

Press Release Oncology Venture issues 1,893,939 shares to Negma Group LTD and Park Partners GP and thereby all outstanding convertible loan notes are converted

Hørsholm, Denmark, 14 August, 2020 – Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) (“OV” or the “Company”) today announces that it will issue 1,893,939 shares at a price per share of SEK 1.32 to Negma Group LTD in order to comply with the Company’s existing convertible loan note agreeme…

Press Release Oncology Venture is issuing 2,255,639 shares under its existing convertible loan note agreement with Negma Group LTD and Park Partners GP

Hørsholm, Denmark, 14 July, 2020 – Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) (“OV” or the “Company”) today announces that it will issue 2,255,639 shares at a price per share of SEK 1.33 to Negma Group LTD in order to comply with the Company’s existing convertible loan note agreement…

Press Release Oncology Venture is issuing 1,574,803 shares under its existing convertible loan note agreement with Negma Group LTD and Park Partners GP

Hørsholm, Denmark, June 30th, 2020 – Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) (“OV” or the “Company”) today announces that it will issue 1,574,803 shares at a price per share of SEK 1.27 to Negma Group LTD in order to comply with the Company’s existing convertible loan note agreeme…

Press release Oncology Venture is issuing 5,177,584 shares under its share subscription agreement with Global Corporate Finance

Hørsholm, Denmark, 18 June, 2020 – Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) (“OV” or the “Company”) today announces that it will issue 5,177,584 shares at a price per share of SEK 1.4968143 to Global Corporate Finance.

Press Release Oncology Venture terminates agreement with liquidity provider

Hørsholm, Denmark, June 11, 2020 – Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) (“OV” or the “Company”) today announces that it has terminated its agreement with the liquidity provider Sedermera Fondkommission. The liquidity warranty will end on August 9, 2020.
Show more

Oncology Venture Frequently Asked Questions

  • When was Oncology Venture founded?

    Oncology Venture was founded in 2004.

  • Who are Oncology Venture key executives?

    Oncology Venture's key executives are Duncan Moore, Henrik Moltke and Frank Knudsen.

  • How many employees does Oncology Venture have?

    Oncology Venture has 12 employees.

  • Who are Oncology Venture competitors?

    Competitors of Oncology Venture include Northwest Biotherapeutics, Merrimack Pharmaceuticals and Genocea Biosciences.

  • Where is Oncology Venture headquarters?

    Oncology Venture headquarters is located at Venlighedsvej 1, Hørsholm.

  • Where are Oncology Venture offices?

    Oncology Venture has offices in Hørsholm and Scottsdale.

  • How many offices does Oncology Venture have?

    Oncology Venture has 2 offices.